Charleston News Online

“Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Chimeric Antigen Receptor T-cell Therapy Market. 

The Chimeric Antigen Receptor T-cell Therapy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Pipeline Analysis

The report provides insights into: 

• The report provides detailed insights into emerging therapies in the Chimeric Antigen Receptor T-cell Therapy Market and the aggregate therapies developed by major pharma companies.

• It accesses the different Chimeric Antigen Receptor T-cell Therapy therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development.

• It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Chimeric Antigen Receptor T-cell Therapy Market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Chimeric Antigen Receptor T-cell Therapies by Phases

This report covers around 300+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Route of Administration

CAR-T pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral

• Subcutaneous

• Intravenous

• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Bispecific Antibody

• Peptides

• Small molecule

• Gene therapy

Learn How the Ongoing Clinical & Commercial Activities will Affect the Chimeric Antigen Receptor T-cell Therapy Therapeutic Segment @ 

https://www.delveinsight.com/sample-request/chimeric-antigen-receptor-t-cell-therapy-car-t-pipeline-insight

Chimeric Antigen Receptor T-cell Therapy Therapeutics Landscape

There are approx. 300+ key companies developing the Chimeric Antigen Receptor T-cell Therapy. Currently, JW Therapeutics is leading the therapeutics market with its CAR-T drug candidates in the most advanced stage, of clinical development.

Leading Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Companies in the Therapeutics Market Include:

• Arcellx, Inc.

• Autolus Therapeutics

• CARsgen

• Cartesian Therapeutics

• CASI Pharmaceuticals

• Celgene Corporation

• Gilead Sciences

• IASO Biotherapeutics

• Juventas Cell Therapy

• JW Therapeutics

• Kite Pharma

• Nexcella, Inc.

• Novartis

• Orgenesis

• Poseida Therapeutics

• Precision BioSciences

• Sana Biotechnology

• Shanghai Unicar-Therapy Bio-medicine Technology

• Sorrento Therapeutics

And Many Others

Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Emerging and Marketed Drugs Covered in the Report Include:

• JWCAR029: JW Therapeutics

• CEA CAR T: Sorrento Therapeutics

• Descartes-11: Cartesian Therapeutics

• CNCT19: CASI Pharmaceuticals/Juventas Cell Therapy

• CTL119: Novartis

• KTE-X19: Gilead Sciences

• CART-19/22: Shanghai Unicar-Therapy Bio-medicine Technology

• P-MUC1C-ALLO1: Poseida Therapeutics

• AUTO-8: Autolus Therapeutics

• CART-ddBCMA: Arcellx, Inc.

• Descartes-011: Cartesian Therapeutics

• Idecabtagene vicleucel: Celgene Corporation

• Axicabtagene ciloleucel: Kite Pharma

• SG299: Sana Biotechnology

• ORGCAR 19.22: Orgenesis

• NXC-201: Nexcella, Inc.

• Azercabtagene zapreleucel: Precision BioSciences

• Zevorcabtagene autoleucel: CARsgen

• Equecabtagene Autoleucel: IASO Biotherapeutics

And Many Others

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

https://www.delveinsight.com/sample-request/chimeric-antigen-receptor-t-cell-therapy-car-t-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Chimeric Antigen Receptor T-cell Therapy Current Treatment Patterns

4. Chimeric Antigen Receptor T-cell Therapy – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Chimeric Antigen Receptor T-cell Therapy Late Stage Products (Phase-III)

7. Chimeric Antigen Receptor T-cell Therapy Mid-Stage Products (Phase-II)

8. Chimeric Antigen Receptor T-cell Therapy Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Chimeric Antigen Receptor T-cell Therapy Discontinued Products

13. Chimeric Antigen Receptor T-cell Therapy Product Profiles

14. Chimeric Antigen Receptor T-cell Therapy Companies in the Market

15. Key Products in the Chimeric Antigen Receptor T-cell Therapy Therapeutics Segment

16. Dormant and Discontinued Products

17. Chimeric Antigen Receptor T-cell Therapy Unmet Needs

18. Chimeric Antigen Receptor T-cell Therapy Future Perspectives

19. Chimeric Antigen Receptor T-cell Therapy Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @ 

https://www.delveinsight.com/sample-request/chimeric-antigen-receptor-t-cell-therapy-car-t-pipeline-insight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Chronic Periodontitis Market

“Chronic Periodontitis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Chronic Periodontitis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Chronic Periodontitis market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/